ReviewJournal of experimental pharmacology2025
Targeting Molecular Pathways in Breast Cancer Using Plant-Derived Bioactive Compounds: A Comprehensive Review.
Review in Journal of experimental pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Cell-Type-Dependent Responses to Oleuropein in MDA-MB-231 Breast Cancer Cells and HUVECs.Cell biochemistry and biophysics · 2026Article
- In vitro study and in silico reveal Teucrium Polium L. methanolic extract as an apoptosis inducer and a potential Bcl-2 inhibitor for breast cancer.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Article
- In Vitro Antineoplastic Effects ofFood science & nutrition · 2026Review
- Plant extracts and phytochemicals in canine and feline mammary cancer models: current evidence and comparative perspectives.Veterinary research communications · 2026Review
- Agro-Industrial Plant Biomass as a Sustainable Source of Anticancer Polyphenols: Molecular Mechanisms and Future Perspectives.Current issues in molecular biology · 2026Review
- Comparative multi-pathway inhibition of breast cancer by micro-and nano-formulated Curcumin.Molecular biology reports · 2026Article
- Advances in quercetin-based therapeutics for breast cancer: natural, synthetic, and nanotechnology-driven approaches.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
- Marine-Derived Steroids for Cancer Treatment: Search for Potential Selective Glucocorticoid Receptor Agonists/Modulators (SEGRAMs).Marine drugs · 2025Review
- Evaluation of Antioxidant-Rich Mexican Oregano (Nutrients · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer remains one of the most prevalent and life-threatening diseases worldwide, affecting millions of individuals and their families. While current treatments such as chemotherapy, radiation, and targeted therapies have improved survival rates, they often come with severe side effects and limitations. This has led to a growing interest in natural compounds derived from medicinal plants as safer and potentially more effective alternatives. These plant-based compounds have shown promise in targeting key cancer pathways, including EGFR, PI3K/AKT/mTOR, NF-κB, JAK-STAT3, RAF/MEK/ERK, BCL-2, p53, and SKP/p21, helping to inhibit tumor growth, induce cancer cell death, and prevent metastasis. Research combining computational, in vitro, and in vivo studies has revealed that bioactive compounds such as flavonoids, alkaloids, and phenolics can provide meaningful therapeutic benefits. However, challenges such as ensuring proper absorption, stability, and clinical application remain. By addressing these limitations through advanced drug formulations and integration into existing treatment plans, plant-based therapies could play a vital role in improving outcomes for breast cancer patients. This review sheds light on the potential of natural compounds to offer hope for more effective and less harmful cancer treatments in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.